These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12369656)

  • 1. A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis.
    Geusens PP; Truitt K; Sfikakis P; Zhao PL; DeTora L; Shingo S; Lau CS; Kalla A; Tate G
    Scand J Rheumatol; 2002; 31(4):230-8. PubMed ID: 12369656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
    Matsumoto AK; Melian A; Mandel DR; McIlwain HH; Borenstein D; Zhao PL; Lines CR; Gertz BJ; Curtis S;
    J Rheumatol; 2002 Aug; 29(8):1623-30. PubMed ID: 12180720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
    Aisen PS; Schafer KA; Grundman M; Pfeiffer E; Sano M; Davis KL; Farlow MR; Jin S; Thomas RG; Thal LJ;
    JAMA; 2003 Jun; 289(21):2819-26. PubMed ID: 12783912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension.
    Reiff A; Lovell DJ; Adelsberg JV; Kiss MH; Goodman S; Zavaler MF; Chen PY; Bolognese JA; Cavanaugh P; Reicin AS; Giannini EH
    J Rheumatol; 2006 May; 33(5):985-95. PubMed ID: 16583464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
    Bombardier C; Laine L; Reicin A; Shapiro D; Burgos-Vargas R; Davis B; Day R; Ferraz MB; Hawkey CJ; Hochberg MC; Kvien TK; Schnitzer TJ;
    N Engl J Med; 2000 Nov; 343(21):1520-8, 2 p following 1528. PubMed ID: 11087881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea.
    Bitner M; Kattenhorn J; Hatfield C; Gao J; Kellstein D
    Int J Clin Pract; 2004 Apr; 58(4):340-5. PubMed ID: 15161117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.
    Hawkey CJ; Laine L; Simon T; Quan H; Shingo S; Evans J;
    Gut; 2003 Jun; 52(6):820-6. PubMed ID: 12740337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group.
    Schnitzer TJ; Truitt K; Fleischmann R; Dalgin P; Block J; Zeng Q; Bolognese J; Seidenberg B; Ehrich EW
    Clin Ther; 1999 Oct; 21(10):1688-702. PubMed ID: 10566565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The optimal analgesic dose of rofecoxib: Overview of six randomized controlled trials.
    Morrison BW; Fricke J; Brown J; Yuan W; Kotey P; Mehlisch D
    J Am Dent Assoc; 2000 Dec; 131(12):1729-37. PubMed ID: 11143737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac.
    Furst DE; Kolba KS; Fleischmann R; Silverfield J; Greenwald M; Roth S; Hall DB; Roszko PJ;
    J Rheumatol; 2002 Mar; 29(3):436-46. PubMed ID: 11908554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration.
    Myllykangas-Luosujärvi R; Lu HS; Chen SL; Choon D; Amante C; Chow CT; Pasero G; Genti G; Sarembock B; Zerbini CA; Vrijens F; Moan A; Rodgers DB; De Tora L; Laurenzi M;
    Scand J Rheumatol; 2002; 31(6):337-44. PubMed ID: 12492248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273].
    Collantes E; Curtis SP; Lee KW; Casas N; McCarthy T; Melian A; Zhao PL; Rodgers DB; McCormick CL; Lee M; Lines CR; Gertz BJ;
    BMC Fam Pract; 2002 May; 3():10. PubMed ID: 12033987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects.
    Hunt RH; Bowen B; Mortensen ER; Simon TJ; James C; Cagliola A; Quan H; Bolognese JA
    Am J Med; 2000 Aug; 109(3):201-6. PubMed ID: 10974182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [No loss of effectiveness with rofecoxib. Long-term control of rheumatoid pain].
    Einecke D
    MMW Fortschr Med; 2002 Nov; 144(46):68. PubMed ID: 12534087
    [No Abstract]   [Full Text] [Related]  

  • 15. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
    Laine L; Connors LG; Reicin A; Hawkey CJ; Burgos-Vargas R; Schnitzer TJ; Yu Q; Bombardier C
    Gastroenterology; 2003 Feb; 124(2):288-92. PubMed ID: 12557133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies.
    Michael Hill C; Sindet-Pederson S; Seymour RA; Hawkesford JE; Coulthard P; Lamey PJ; Gerry Cowan C; Wickens M; Jeppsson L; Dean AD; Svensson O
    Clin Ther; 2006 Sep; 28(9):1279-95. PubMed ID: 17062301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rofecoxib for rheumatoid arthritis.
    Garner SE; Fidan DD; Frankish RR; Judd MG; Towheed TE; Wells G; Tugwell P
    Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD003685. PubMed ID: 15674912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production.
    Wight NJ; Gottesdiener K; Garlick NM; Atherton CT; Novak S; Gertz BJ; Calder NA; Cote J; Wong P; Dallob A; Hawkey CJ
    Gastroenterology; 2001 Mar; 120(4):867-73. PubMed ID: 11231941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.
    Ehrich EW; Schnitzer TJ; McIlwain H; Levy R; Wolfe F; Weisman M; Zeng Q; Morrison B; Bolognese J; Seidenberg B; Gertz BJ
    J Rheumatol; 1999 Nov; 26(11):2438-47. PubMed ID: 10555907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen.
    Ta LE; Dionne RA
    Pain; 2004 Sep; 111(1-2):13-21. PubMed ID: 15327804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.